原发性高血压治疗药物相关基因多态性的研究进展  

Research Progress of Drug Related Gene Polymorphism for Essential Hypertension

作　　者：王婷婷[1] 赵玲莉[2] 

机构地区：[1]青海大学临床医学院,青海 西宁 [2]青海大学附属医院检验科,青海 西宁

出　　处：《医学诊断》2024年第1期28-32,共5页Medical Diagnosis

摘　　要：原发性高血压是由遗传和环境两大因素综合影响的结果,这是一种由多个基因共同作用导致的遗传性疾病,现今通过药物来控制血压是主要的治疗和降低相关并发症的策略。然而,在临床实践中,降压药物之间的个体差异非常常见,这主要基于降血压药物代谢酶、受体及其他药物相关基因的突变差异。抗高血压药物基因多态性研究对于改进现有的药物和探索新的降压药物具有重要作用。本文对原发性高血压普遍的治疗药物相关基因多态性研究进展进行综述,为后续基于个体差异的原发性高血压患者的治疗提供精准的理论基础。Essential hypertension is a combination of genetic and environmental factors, which is a genetic disease caused by multiple genes. At present, controlling blood pressure through drugs is the main treatment strategy and reducing related complications. However, in clinical practice, individual dif-ferences between blood pressure lowering drugs are very common, which is mainly based on dif-ferences in mutations of blood pressure lowering drug metabolizing enzymes, receptors and other drug-related genes. The study of gene polymorphism of antihypertensive drugs plays an important role in improving existing drugs and exploring new antihypertensive drugs. This article reviews the research progress of drug related gene polymorphism in the treatment of essential hypertension, which provides a theoretical basis for providing accurate treatment for essential hypertension pa-tients according to individual differences.

关 键 词：原发性高血压 高血压药物相关基因 基因组学 基因多态性 

分 类 号：R54[医药卫生—心血管疾病]